DE69924232D1 - Stabilisierte insulin-zubereitungen - Google Patents

Stabilisierte insulin-zubereitungen

Info

Publication number
DE69924232D1
DE69924232D1 DE69924232T DE69924232T DE69924232D1 DE 69924232 D1 DE69924232 D1 DE 69924232D1 DE 69924232 T DE69924232 T DE 69924232T DE 69924232 T DE69924232 T DE 69924232T DE 69924232 D1 DE69924232 D1 DE 69924232D1
Authority
DE
Germany
Prior art keywords
insulin preparations
stabilized insulin
glycylglycine
analogue
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924232T
Other languages
English (en)
Inventor
Peter Langballe
Elsebeth Norup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69924232D1 publication Critical patent/DE69924232D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69924232T 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen Expired - Lifetime DE69924232D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98610001 1998-01-09
PCT/DK1999/000006 WO1999034821A1 (en) 1998-01-09 1999-01-06 Stabilised insulin compositions

Publications (1)

Publication Number Publication Date
DE69924232D1 true DE69924232D1 (de) 2005-04-21

Family

ID=8235844

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924232T Expired - Lifetime DE69924232D1 (de) 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen

Country Status (7)

Country Link
US (1) US6174856B1 (de)
EP (1) EP1044016B1 (de)
JP (1) JP2002500196A (de)
AT (1) ATE290877T1 (de)
AU (1) AU1870099A (de)
DE (1) DE69924232D1 (de)
WO (1) WO1999034821A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ATE220917T1 (de) * 1999-01-26 2002-08-15 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
DE60138572D1 (de) * 2000-07-31 2009-06-10 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030158670A1 (en) * 2001-12-04 2003-08-21 Philip Hougaard Method of planning and performing stability studies
WO2003075950A1 (en) * 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
WO2003094951A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20040126831A1 (en) * 2002-12-31 2004-07-01 Medtronic Minimed, Inc. Functionalization of immobilized proteins
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
NZ545086A (en) * 2003-08-07 2011-06-30 Healor Ltd Pharmaceutical compositions and methods for accelerating wound healing
PL1773878T3 (pl) * 2004-07-19 2015-07-31 Biocon Ltd Koniugaty insulina-oligomer, ich formulacje i zastosowania
JP4874989B2 (ja) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス 可溶性で安定なインスリン含有調合物
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
CA2625674C (en) 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
ATE519780T1 (de) * 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
ATE482977T1 (de) * 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
US8933021B2 (en) * 2006-05-09 2015-01-13 Novo Nordisk A/S Insulin derivative
JP5269766B2 (ja) * 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
EP2167032B1 (de) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmazeutische formulierung enthaltend ein insulinderivat
CN101835486B (zh) * 2007-07-30 2012-12-12 希尔洛有限公司 用于治疗创伤的药物组合物以及相关方法
KR101234540B1 (ko) * 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
CN101932601B (zh) * 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
EP2113564A1 (de) * 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
FR2932908B1 (fr) * 2008-06-24 2012-11-16 Arjowiggins Licensing Sas Structure comportant un filigrane ou pseudo-filigrane et un dispositif a microcircuit integre.
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102202683A (zh) * 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
MX2011007929A (es) 2009-01-28 2011-08-17 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada.
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
KR101852328B1 (ko) * 2009-07-06 2018-04-26 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
WO2011049776A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically effective preparations of insulin
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
WO2011083482A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of psoriasis
EP2590667A4 (de) * 2010-07-07 2013-11-27 Biodel Inc Zusammensetzungen und verfahren zur modulation der pharmakokinetik und pharmakodynamik von insulin
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
CA2889552C (fr) 2012-11-13 2023-10-10 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CA2889165A1 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
WO2016137569A1 (en) * 2015-02-25 2016-09-01 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US11207384B2 (en) 2017-06-01 2021-12-28 Eli Lilly And Company Rapid-acting insulin compositions
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
CA3198757A1 (en) 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU550068B2 (en) 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
JP2628340B2 (ja) * 1988-05-14 1997-07-09 株式会社いかがく 血液中のインシュリン成分の安定方法
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
JP2837956B2 (ja) * 1993-06-21 1998-12-16 ノボ ノルディスク アクティーゼルスカブ Ａｓｐ▲上Ｂ２８▼インスリン結晶
RO112873B1 (ro) * 1993-09-17 1998-01-30 Novo Nordisk As Derivati de insulina
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
ATE208208T1 (de) * 1996-06-20 2001-11-15 Novo Nordisk As Halogenid-enthaltende insulinzubereitungen

Also Published As

Publication number Publication date
EP1044016A1 (de) 2000-10-18
WO1999034821A1 (en) 1999-07-15
AU1870099A (en) 1999-07-26
US6174856B1 (en) 2001-01-16
ATE290877T1 (de) 2005-04-15
JP2002500196A (ja) 2002-01-08
EP1044016B1 (de) 2005-03-16

Similar Documents

Publication Publication Date Title
DE69924232D1 (de) Stabilisierte insulin-zubereitungen
DK1175149T3 (da) Desinficerende sammensætning baseret på H2O2, syrer og metaliioner
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
BR0107811B1 (pt) composiÇço herbicida seletiva e mÉtodos de controle de plantas.
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
HK1025740A1 (en) Stable pharmaceutical composition of hedgehof proteins and use thereof.
IL127366A0 (en) Insulin preparations containing NaCl
NO20012994D0 (no) Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
NO20015471D0 (no) Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
NO20031860L (no) Kahalalid F
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
NO20024760L (no) Stabil og effektiv myk, fast antiperspirant og/eller deodorant
DE60131085D1 (de) Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika
DE69927795D1 (en) Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
MXPA03004539A (es) Luciferasas aisladas y uso de las mismas.
RS50355B (sr) Formulacije eritropoietina sa više doza
MY138219A (en) Biologically active peptides
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
DE69813833T2 (de) 4-cyano-4-deformylsordarizin-derivate
DE69815355D1 (de) 4-cyano-4-deformylsordarinderivate
SE9502927D0 (sv) Solution containing IGF-I
ATE179075T1 (de) Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine
BR0003780B1 (pt) composições contendo espécies de oxigênio instável e método para estabilizar composições contendo espécies de oxigênio instável.

Legal Events

Date Code Title Description
8332 No legal effect for de